AR and neoplasm: In particular, eligibility requirements for the prostate cancer trial [82] required castrate levels of serum testosterone (≤50 ng/mL), and decreased AR-activity may have caused a downregulation of SLC35F2 that prevented effective tumor uptake of YM155.